GLP-1 for Adults 60+: SELECT Trial Benefits and Muscle Loss Risk

Obesity in older adults carries the same health risks as in younger adults

The first thing to understand is this: obesity does not become less of a health concern when you turn 60. Cardiovascular disease, type 2 diabetes, joint pain, reduced mobility, and metabolic dysfunction are just as clinically significant at 65 as they are at 45. In fact, for older adults, the functional impact of excess weight on independence and quality of life can be even more pronounced.

If you are over 60 and have been struggling with your weight, you may have been told that dieting at your age is harder. That is true. But the problem is not age itself. The problem is that the traditional calorie-deficit approach does not account for how your body’s hormonal and metabolic systems have changed. That is one reason GLP-1 medications are worth understanding.

The SELECT trial: specific evidence for adults over 60

The most relevant clinical trial for older adults considering GLP-1 treatment is the SELECT trial, published in 2023 in the New England Journal of Medicine^[1]. It enrolled adults 45 and older with existing cardiovascular disease (such as a prior heart attack or stroke), a BMI of 27 or higher, and no diabetes. The mean age was about 62.

The trial randomized 17,604 participants to receive either semaglutide 2.4 mg weekly or placebo. The primary outcome was major adverse cardiovascular events: cardiovascular death, non-fatal heart attack, or non-fatal stroke.

Over a mean follow-up of 39.8 months, a primary event occurred in 6.5% of people on semaglutide and 8.0% on placebo, a 20% relative reduction in risk^[1]. According to the Wegovy label, 30% of semaglutide-treated patients in this trial were 65 to 75 and 8% were 75 or older^[3]. For older adults with existing cardiovascular disease, this evidence is directly applicable.

A later analysis reported weight outcomes. At 208 weeks, average weight change was -10.2% with semaglutide vs -1.5% with placebo, and weight loss was sustained for up to 4 years in people who stayed on treatment^[2]. Results vary, and trial averages are not a prediction for any individual. SELECT tested the brand-name product, and its results do not apply to compounded semaglutide.

Older adults respond to GLP-1 medication as effectively as younger adults

One question you may have is whether GLP-1 medications work as well for weight loss at 60 or 70 as they do at 40. The available data points in that direction.

The FDA labels summarize what the trials found by age. The Wegovy (semaglutide) label reports no overall difference in effectiveness between patients 65 and older and younger adults in the cardiovascular outcomes trial^[3]. The Zepbound (tirzepatide) label reports no overall differences in safety or effectiveness between patients 65 and older and younger adults in its weight reduction trials, although only about 9% of tirzepatide-treated patients in those trials were 65 or older^[4].

The main weight-loss trials, STEP 1 (semaglutide)^[5] and SURMOUNT-1 (tirzepatide)^[6], enrolled adults across a wide age range, and their headline results are averages for everyone enrolled rather than separate results for older adults. Results vary by individual.

The core age-specific concern: sarcopenia and muscle loss

The key distinction for older adults on GLP-1 medications is not only whether weight comes off. It is about what kind of weight you lose and at what rate.

Sarcopenia, or age-related loss of muscle mass and strength, is already a concern in adults 60 and older^[7]. Muscle mass and strength decline gradually with age, and the decline tends to speed up in later decades. This is a natural part of aging.

Muscle loss in older adults has real consequences. Sarcopenia is associated with falls, fractures, physical disability, and higher mortality^[8]. It is not just a cosmetic concern.

When you lose weight, you lose both fat and lean mass (muscle, bone, and other tissues). The proportion varies. In a body-composition substudy of SURMOUNT-1, roughly a quarter of the weight lost was lean mass rather than fat^[6]; other studies have reported different proportions.

For a 45-year-old losing 40 pounds, a quarter would mean about 10 pounds of lean mass. For a 68-year-old losing the same 40 pounds, the same lean mass loss is more clinically significant because of lower baseline muscle reserve and reduced capacity to rebuild.

This is not a reason to avoid GLP-1 treatment. It is a reason to structure your plan specifically to minimize muscle loss through resistance training and adequate protein intake.

Protein intake and resistance training: non-negotiable for older adults on GLP-1

If you are 60 or older and starting GLP-1 medication, your nutrition and exercise approach needs to be intentional about muscle preservation.

Protein targets: The PROT-AGE expert group recommends that adults over 65 get at least 1.0 to 1.2 grams of protein per kilogram of body weight daily, at least 1.2 g/kg if they are exercising or otherwise active, and 1.2 to 1.5 g/kg for most older adults with acute or chronic disease^[9]. For a 170-pound (77 kg) person, 1.2 g/kg is about 92 grams of protein per day. The same group notes an exception: people with severe kidney disease who are not on dialysis may need to limit protein. Ask your provider or a registered dietitian what target fits you.

When appetite is suppressed by GLP-1, hitting these protein targets requires intention. Prioritize protein-rich foods at each meal. Consider protein shakes or supplements if you are not hitting targets through food alone.

Resistance training: The Physical Activity Guidelines for Americans recommend muscle-strengthening activity at least 2 days a week, and multicomponent activity that includes balance training for older adults^[10]. This includes weight training, resistance bands, bodyweight exercises (squats, push-ups), or any structured approach that creates muscle tension and stimulates strength adaptation. Aim for at least 8-10 repetitions of exercises targeting major muscle groups.

Resistance training is not optional. It is what signals your body to preserve muscle during weight loss. Without it, a larger share of the weight you lose may come from muscle.

Bone density and substantial weight loss in older adults

Bone density naturally declines with age, particularly for women after menopause. Substantial weight loss is associated with reductions in bone mineral density. Whether GLP-1 medications themselves add to that effect is not settled.

The Wegovy label reports that in the SELECT trial, patients 75 and older reported more hip and pelvis fractures on semaglutide than on placebo^[3]. For adults 60 and older, particularly those with existing osteoporosis or osteopenia, bone health warrants attention.

What to do: Get the recommended calcium and vitamin D. The Institute of Medicine’s Recommended Dietary Allowances are 1,000 to 1,200 mg of calcium daily for adults over 50 (depending on age and sex), and 600 IU of vitamin D daily through age 70 and 800 IU from age 71^[11]. Weight-bearing and resistance exercise also support bone health.

Your provider may recommend a baseline DXA scan (bone density scan) before starting treatment if you have risk factors for bone density loss, and follow-up monitoring during treatment. This is not required for everyone but is appropriate for those with significant osteoporosis risk or prior fractures.

Gastrointestinal side effects in older adults

The most common side effects of GLP-1 medications are gastrointestinal: nausea, constipation, diarrhea, and reduced appetite. In the trials, these were usually mild to moderate and eased with time for many people^[5], but in older adults, these side effects warrant particular attention.

Dehydration risk: Older adults have a reduced thirst sensation and lower total body water. Vomiting or diarrhea from GLP-1 side effects carries a higher dehydration risk in older people. Both FDA labels warn about acute kidney injury, in some cases requiring dialysis, mostly in people who became dehydrated from nausea, vomiting, or diarrhea, and the Wegovy label notes the risk of kidney-related side effects was higher in people with a history of kidney impairment^[3][4]. Dehydration can also contribute to falls and confusion.

Slower dose escalation: The labels allow a provider to delay a dose increase if a dose is not tolerated^[3][4]. Your provider may recommend escalating more slowly than the standard schedule, which gives your gastrointestinal system more time to adapt.

Monitoring: Stay hydrated. Drink water consistently throughout the day, not just when you feel thirsty. If you experience persistent vomiting or diarrhea, contact your provider. These side effects often ease, but if they do not, a dose adjustment may be needed.

Polypharmacy: GLP-1 and multiple medications

Most older adults take multiple medications for blood pressure, cholesterol, heart rhythm, or other conditions. GLP-1 medications slow gastric emptying, which can affect how other oral medications are absorbed^[3][4].

Some oral medications require consistent absorption for their effect. The labels call for closer monitoring of oral medications with a narrow therapeutic index, such as the blood thinner warfarin^[4]. Blood pressure medications, hormone therapies, and diabetes medications are also worth reviewing with your provider.

This does not mean you cannot take GLP-1 if you are on other medications. It means you need clear communication with your provider about your complete medication list. Your provider may:

• Review the timing of your other medications
• Check whether any require special spacing or dosing adjustments with GLP-1
• Monitor your clinical response more closely
• Adjust doses if needed

This is routine clinical work, not a barrier to treatment. But it is essential that you disclose all medications and supplements to your provider before starting.

Menopause and perimenopause context for women 50-65

If you are a woman in your 50s or early 60s, you may overlap with menopause. Estrogen decline during menopause and perimenopause contributes to multiple changes that compound the challenges of weight loss at this life stage.

Estrogen influences where your body stores fat (perimenopause often shifts fat distribution toward the abdomen), how your metabolism works, and how your appetite-regulating hormones function. Estrogen also supports bone density and muscle mass. As estrogen declines, your bone density naturally decreases, and your muscle loss accelerates.

If you are considering GLP-1 treatment during perimenopause or early menopause, the protein intake and resistance training recommendations above are even more important. You are fighting against multiple biological forces at the same time: estrogen decline, age-related muscle loss, and the muscle-loss effect of substantial weight loss.

Some people on GLP-1 treatment also use hormone therapy. This is a conversation to have with your provider. Hormone therapy is not listed as a contraindication on the GLP-1 labels, but the combination should be coordinated.

Who is appropriate for GLP-1 treatment, and who requires extra consideration

Only a licensed provider can decide whether a GLP-1 prescription is appropriate for you. These are the factors providers commonly weigh for older adults.

Situations where GLP-1 treatment is often considered: Older adults with obesity, or overweight with a weight-related condition, who have no contraindications, adequate nutrition, and the ability to keep up resistance training and protein intake.

Adults with obesity and existing cardiovascular disease, type 2 diabetes, joint pain limiting mobility, or other weight-related conditions are often the focus of these conversations. For some people, even modest weight loss can make daily movement easier.

Situations that call for extra caution: Older adults with pre-existing sarcopenia or frailty (very low muscle mass or strength), severe untreated osteoporosis, chronic kidney disease (the labels warn that dehydration from GI side effects can cause acute kidney injury), significant polypharmacy where drug interactions are complex, or very limited capacity to do resistance training or maintain adequate nutrition.

These people may still be candidates for GLP-1 treatment, but they need more careful provider oversight and may benefit from a different approach (slower dose escalation, lower target doses, more frequent monitoring).

The case for GLP-1 in older adults despite the age-specific considerations

Obesity in older adults is not less important than obesity at 40. Cardiovascular disease, mobility impairment, reduced quality of life, and metabolic disease are real problems at any age. They matter more, not less, because they directly affect independence and how long you can maintain the life you want to live.

GLP-1 medications have been studied in older adults. The SELECT trial, with a mean participant age of about 62, showed a 20% relative reduction in major cardiovascular events with semaglutide 2.4 mg^[1], and the FDA labels report no overall difference in effectiveness for patients 65 and older^[3][4].

The muscle loss and bone density concerns are real. Resistance training and adequate protein intake are not exotic interventions. They are evidence-based approaches that most older adults can do, and with regular monitoring they can help lower the age-specific risks.

How the process should work

At most telehealth programs, a licensed provider (a physician, nurse practitioner, or physician assistant) reviews your health history and decides whether a prescription is appropriate. For an older adult, a careful review covers your age, any cardiovascular events, current medications, kidney function, bone health if available, and your capacity for exercise and nutrition changes.

If you are 60 or older, expect the provider to discuss the age-specific considerations with you:

• The muscle loss risk and the importance of resistance training and protein intake
• The potential for bone density effects and whether baseline monitoring is appropriate
• Your complete medication list and potential interactions
• Your capacity and willingness to do resistance training
• Whether a slower dose escalation schedule is appropriate given your GI tolerance or overall health

Before you choose a program, ask:

• Will the prescriber review your full medication list and coordinate with your primary care provider? This matters most if you take blood thinners, blood pressure medications, or diabetes medications.
• Are labs included or billed separately? Some programs include baseline and follow-up labs, such as kidney function; others bill separately or ask you to get them through your own provider.
• How are dose increases handled? Ask how often the prescriber checks in during escalation and whether a slower schedule is an option.
• Is nutrition and exercise support included? Some programs offer guidance on protein and resistance training; many do not.
• Is the medication brand-name or compounded? Compounded medications are not FDA-approved, and the FDA does not review them for safety, effectiveness, or quality.
• What is the total cost? Compare medication, dose increases, provider visits, labs, shipping, membership fees, and cancellation terms. Prices vary by program and dose.

Transformation Health does not accept payment from providers. How we make money.

What to check before using compounded semaglutide or tirzepatide

Some telehealth programs prescribe compounded semaglutide or tirzepatide, prepared by state-licensed compounding pharmacies. Compounded medications are not FDA-approved. The FDA does not review them for safety, effectiveness, or quality, and they may differ from brand-name products in formulation, purity, or potency. Compounded semaglutide and tirzepatide are not the same as brand-name products such as Wegovy or Zepbound.

The clinical trials on this page, including SELECT, STEP 1, and SURMOUNT-1, studied the FDA-approved products. Their results do not apply directly to compounded versions.

If a program offers a compounded medication, ask which pharmacy prepares it, whether that pharmacy is licensed in your state, whether the medication contains added ingredients and why, and how the dose is measured. A licensed provider decides which medication and dose, if any, is appropriate for you.

How to get started

Before any visit, write down your age-related health concerns, your cardiovascular history, your complete medication and supplement list, your exercise capacity, and your goals. Being specific helps the provider evaluate muscle loss risk, bone health, medication interactions, and whether your situation calls for special precautions.

Transformation Health is relaunching as an independent GLP-1 guide with a free custom report that compares programs. Leave your email to be told when the report is available.

Citations

[1] Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” New England Journal of Medicine. 2023;389(24):2221-2232. https://pubmed.ncbi.nlm.nih.gov/37952131/

[2] Ryan DH, et al. “Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial.” Nature Medicine. 2024;30(7):2049-2057. https://pubmed.ncbi.nlm.nih.gov/38740993/

[3] Novo Nordisk. Wegovy (semaglutide) prescribing information, sections 2, 5.5, 7.2, and 8.5. Revised 06/2026 (NDA 215256, supplement 25). Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/215256s025lbl.pdf

[4] Eli Lilly and Company. Zepbound (tirzepatide) prescribing information, sections 2, 5.3, 7.2, 8.5, and 8.6. Revised 08/2026 (NDA 217806, supplement 41). Accessed 2026-10-16. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806Orig1s041correctedlbl.pdf

[5] Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/

[6] Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/

[7] Rosenberg IH. “Sarcopenia: Origins and Clinical Relevance.” Journal of Nutrition. 1997;127(5 Suppl):990S-991S. https://pubmed.ncbi.nlm.nih.gov/9164280/

[8] Cruz-Jentoft AJ, et al. “Sarcopenia: revised European consensus on definition and diagnosis.” Age and Ageing. 2019;48(1):16-31. https://pubmed.ncbi.nlm.nih.gov/30312372/

[9] Bauer J, et al. “Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group.” Journal of the American Medical Directors Association. 2013;14(8):542-559. https://pubmed.ncbi.nlm.nih.gov/23867520/

[10] Piercy KL, et al. “The Physical Activity Guidelines for Americans.” JAMA. 2018;320(19):2020-2028. https://pubmed.ncbi.nlm.nih.gov/30418471/

[11] Ross AC, et al. “The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know.” Journal of Clinical Endocrinology and Metabolism. 2011;96(1):53-58. https://pubmed.ncbi.nlm.nih.gov/21118827/